Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Cited by (588)

Items 101–200 of 588

1. The Role of Emerging Risk Factors in Cardiovascular Outcomes
   Ben Lacey, William Guy Herrington, David Preiss, Sarah Lewington, Jane Armitage · 2017 · Current Atherosclerosis Reports
2. RETRACTED ARTICLE: Kynurenine promotes neonatal heart regeneration by stimulating cardiomyocyte proliferation and cardiac angiogenesis
   Donghong Zhang, Jinfeng Ning, Tharmarajan Ramprasath, Changjiang Yu, Xiaoxu Zheng, Ping Song, Zhonglin Xie, Ming‐Hui Zou · 2022 · Nature Communications · Retracted
3. Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults
   Wang, Baihan, Pozarickij, Alfred, Mazidi, Mohsen, Wright, Neil, Yao, Pang, Said, Saredo, Iona, Andri, Kartsonaki, Christiana, Fry, Hannah, Lin, Kuang et al. · 2025 · Nature Communications
4. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications
   Giuseppe Maiolino · 2015 · World Journal of Cardiology
5. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities
   Jay Khambhati, Marc Engels, Marc Allard‐Ratick, Pratik B. Sandesara, Arshed Ali Quyyumi, Laurence S. Sperling · 2018 · Atherosclerosis
6. Anti-inflammatory therapy for cardiovascular disease
   Constantine E. Kosmas, Delia Silverio, Andreas Sourlas, Peter D. Montan, Eliscer Guzman, Mario J. García · 2019 · Annals of Translational Medicine
7. Atherosclerosis and inflammation. New therapeutic approaches
   Juan Pedro‐Botet, Elisenda Climent, David Benaiges · 2020 · Medicina Clínica (English Edition)
8. Combating Inflammation in Cardiovascular Disease
   A. Sethwala, Ian Y Goh, John V. Amerena · 2020 · Heart Lung and Circulation
9. Inhibitors of phospholipase A2and their therapeutic potential: an update on patents (2012-2016)
   Maroula G. Kokotou, Dimitris Limnios, Aikaterini I. Nikolaou, Anastasia Psarra, George Kokotos · 2016 · Expert Opinion on Therapeutic Patents
10. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population
    Hirotsugu Ueshima, Takashi Kadowaki, Takashi Hisamatsu, Akira Fujiyoshi, Katsuyuki Miura, Takayoshi Ohkubo, Akira M Sekikawa, Aya Kadota, Sayaka Kadowaki, Yasuyuki Nakamura et al. · 2015 · Atherosclerosis
11. Impact of Plasma Lp-PLA2 Activity on the Progression of Aortic Stenosis
    Capoulade, Romain, Mahmut, Ablajan, Tastet, Lionel, Arsenault, Marie, Bédard, Élisabeth, Dumesnil, Jean G., Després, Jean-Pierre, Larose, Éric, Arsenault, Benoit J., Bossé, Yohan et al. · 2015 · JACC: Cardiovascular Imaging
12. Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial
    Peter Lindsay Thompson, Stefan Mark Nidorf · 2018 · Journal of Thoracic Disease
13. Harnessing the early post-injury inflammatory responses for cardiac regeneration
    Bill Cheng, Hung-Chih Chen, I-Wen Chou, Tony Wen-Hung Tang, Patrick C.H. Hsieh · 2017 · Journal of Biomedical Science
14. Tooth loss is independently associated with poor outcomes in stable coronary heart disease
    Ola Vedin, Emil Hagström, Andrzej Budaj, Stephan Denchev, Robert A. Harrington, Wolfgang Köenig, Joseph Soffer, Piyamitr Sritara, Amanda Stebbins, Ralph HA Stewart et al. · 2015 · European Journal of Preventive Cardiology
15. Targeting Inflammation to Reduce Residual Cardiovascular Risk
    Ajala, Oluremi N., Everett, Brendan M. · 2020 · Current Atherosclerosis Reports
16. Targeting Inflammation After Acute Myocardial Infarction
    Antonino Imbesi, Antonio Greco, Marco Spagnolo, Claudio Laudani, Carmelo Raffo, Simone Finocchiaro, Placido Maria Mazzone, Davide Landolina, Maria Sara Mauro, Luigi Cutore et al. · 2025 · Journal of the American College of Cardiology
17. Treating Coronary Disease and the Impact of Endothelial Dysfunction
    Yasushi Matsuzawa, Raviteja Reddy Guddeti, Taek‐Geun Kwon, Lilach O. Lerman, Amir Lerman · 2014 · Progress in Cardiovascular Diseases
18. Failure to Launch
    Jennifer A. Rymer, Laura Kristin Newby · 2017 · JACC Basic to Translational Science
19. Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis
    Dongze Li, Lizhi Zhao, Jing Yu, Wei Zhang, Rongsheng Du, Xin Liu, Ying Liu, You Chen, Rui Zeng, Yu Cao et al. · 2016 · Clinica Chimica Acta
20. Platelet-activating factor acetylhydrolases: An overview and update
    Nozomu Kono, Hiroyuki Arai · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
21. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis
    Francis O'Neill, Marietta Charakida, Eric Topham, Eve McLoughlin, Neha P Patel, Emma Sutill, Christopher W. M. Kay, Francesco D’Aiuto, Ulf Landmesser, Peter Charles Taylor et al. · 2016 · Heart
22. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study
    Andrew Maxwell Tonkin, Stefan Blankenberg, Adrienne C Kirby, Tanja Zeller, David M. Colquhoun, Anne Funke-Kaiser, Wendy E. Hague, David U. Hunt, ANTHONY C. KEECH, Paul John Nestel et al. · 2015 · International Journal of Cardiology
23. Association of Lp-PLA 2 -A and early recurrence of vascular events after TIA and minor stroke
    Jinxi Lin, Hongwei Zheng, Brett L. Cucchiara, Jiejie Li, Xingquan Zhao, Xianhong Liang, Chunxue Wang, Hao Li, Michael T. Mullen, S. Claiborne Johnston et al. · 2015 · Neurology
24. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
    Christian Weber, Lina Badimón, François Mach, Emiel P. C. van der Vorst · 2017 · Thrombosis and Haemostasis
25. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
    Dunbar, Richard L., Nicholls, Stephen J., Maki, Kevin C., Roth, Eli M., Orloff, David G., Curcio, Danielle, Johnson, Judith, Kling, Douglas, Davidson, Michael H. · 2015 · Lipids in Health and Disease
26. Imaging Plaques to Predict and Better Manage Patients With Acute Coronary Events
    Héctor M. García‐García, Ik‐Kyung Jang, Patrick W.J.C. Serruys, Jason Ciril Kovacic, Jagat Narula, Zahi Adel Fayad · 2014 · Circulation Research
27. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
    Kevin O’Fee, Elena Deych, Oriana Ciani, David Brown · 2021 · JAMA Internal Medicine
28. Integrated analysis of single-cell and bulk RNA sequencing reveals pro-fibrotic PLA2G7high macrophages in pulmonary fibrosis
    Junyi Wang, Manling Jiang, Anying Xiong, Lei Zhang, Li Luo, Yao Liu, Shengbin Liu, Ran Qin, Dehong Wu, Ying Xiong et al. · 2022 · Pharmacological Research
29. Oxidized phospholipids and lipoprotein‐associated phospholipase A2 ( Lp‐PLA2 ) in atherosclerotic cardiovascular disease: An update
    Despoina Pantazi, Constantinos C. Tellis, Alexandros D. Tselepis · 2022 · BioFactors
30. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV
    Eric Nou, Michael T. Lu, Sara E. Dolan Looby, Kathleen V. Fitch, Elli A. Kim, Hang Lee, Udo Hoffmann, Steven Kyle Grinspoon, Janet Lo · 2015 · AIDS
31. Immune-mediated mechanisms of atherosclerosis and implications for the clinic
    Meritxell Nus, Ziad Mallat · 2016 · Expert Review of Clinical Immunology
32. Colchicine in ischemic heart disease: the good, the bad and the ugly
    Domenico D’Amario, Donato Cappetta, Luigi Cappannoli, Giuseppe Princi, Stefano Migliaro, Giovanni Diana, Karim Chouchane, Josip A. Borovac, Attilio Restivo, Alessandra Arcudi et al. · 2021 · Clinical Research in Cardiology
33. Modern Concepts in Cardiovascular Disease: Inflamm-Aging
    Yustina M. Puspitasari, Stefano Ministrini, Lena Schwarz, Caroline Karch, Luca Liberale, Giovanni Guido Camici · 2022 · Frontiers in Cell and Developmental Biology
34. Molecular biology of calcific aortic valve disease: towards new pharmacological therapies
    Patrick Mathieu, Marie‐Chloé Boulanger, Rihab Bouchareb · 2014 · Expert Review of Cardiovascular Therapy
35. Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role
    D. Alexandros · 2016 · Journal of Biomedical Research
36. pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics
    Vittorio E. Caprio, Lina Badimón, Mario Di Napoli, Wen-Hui Fang, Glenn R. Ferris, Baoqiang Guo, Rocco S. Iemma, Donghui Liu, Yasmin Zeinolabediny, MARK A. SLEVIN · 2018 · Frontiers in Immunology
37. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
    Marie-Jeanne Bertrand, Jean‐Claude Tardif · 2016 · Expert Opinion on Emerging Drugs
38. Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
    Ralph Stewart, Claes Held, Sue Krug‐Gourley, Dawn M. Waterworth, Amanda S. Stebbins, Karen Chiswell, Emil Hagström, Paul W. Armstrong, Lars C. Wallentin, Harvey Douglas White · 2019 · Journal of the American Heart Association
39. Genome‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records
    Jamie R. Robinson, Joshua C. Denny, Dan M. Roden, Sara L. Van Driest · 2017 · Clinical and Translational Science
40. Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease
    Philippa J. Talmud, Michael Vaclav Holmes · 2015 · Arteriosclerosis Thrombosis and Vascular Biology
41. La Lp-PLA2, marqueur d’inflammation vasculaire et de vulnérabilité de la plaque d’athérosclérose
    Dominique Bonnefont‐Rousselot · 2015 · Annales Pharmaceutiques Françaises
42. Contribution of Inflammation and Hypoperfusion to White Matter Hyperintensities-Related Cognitive Impairment
    Chaojuan Huang, Xia Zhou, Xin Yuan, Wei Zhang, Mingxu Li, Mengzhe You, Xiaoqun Zhu, Zhongwu Sun · 2022 · Frontiers in Neurology
43. Update of the risk assessment of mineral oil hydrocarbons in food
    EFSA Panel on Contaminants in the Food Chain (CONTAM), Dieter Schrenk, Margherita Bignami, Laurent Bodin, Jesús del Mazo, Bettina Grasl‐Kraupp, Christer Högstrand, Laurentius A. P. Hoogenboom, Jean‐Charles Leblanc, Carlo Nebbia et al. · 2023 · EFSA Journal
44. Serum untargeted lipidomic profiling reveals dysfunction of phospholipid metabolism in subclinical coronary artery disease
    Demir Djekic, Rui Climaco Pinto, Dirk Repsilber, Tuulia Hyötyläinen, Michael Y. Henein · 2019 · Vascular Health and Risk Management
45. Biomarkers of Plaque Instability
    Prediman K. Shah · 2014 · Current Cardiology Reports
46. Updating concepts on atherosclerotic inflammation: From pathophysiology to treatment
    Stefano Ministrini, Federico Carbone, Fabrizio Montecucco · 2020 · European Journal of Clinical Investigation
47. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials
    Gabriella Passacquale, Paolo Di Giosia, Albert Ferro · 2015 · Cardiovascular Research
48. Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome
    Robert S. Rosenson, H. Bryan Brewer, Daniel James Rader · 2014 · Circulation Research
49. Low-dose i nterleukin 2 for the reduction of v ascular inflammati o n in acute corona ry syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial
    Rouchelle Sriranjan, Tian Xiao Zhao, Jason M. Tarkin, Annette Hubsch, Joanna Helmy, Evangelia Vamvaka, Navazh Jalaludeen, Simon James Bond, Stephen Paul Hoole, Philip Knott et al. · 2022 · BMJ Open
50. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema
    Giovanni Staurenghi, Li Ye, Mindy He Magee, Ronald P. Danis, John I. Wurzelmann, Peter Adamson, Megan McLaughlin · 2015 · Ophthalmology
51. Deposition and hydrolysis of serine dipeptide lipids of Bacteroidetes bacteria in human arteries: relationship to atherosclerosis
    Reza Nemati, Christopher J. Dietz, Emily J. Anstadt, Jorge Cervantes, Yaling Liu, Floyd E. Dewhirst, Robert Brown Clark, Sydney M. Finegold, James J. Gallagher, Michael B. Smith et al. · 2017 · Journal of Lipid Research
52. A phenome-wide association study of a lipoprotein-associated phospholipase A2loss-of-function variant in 90 000 Chinese adults
    Iona Y. Millwood, Derrick Bennett, Robin G. Walters, Robert Clarke, Dawn M. Waterworth, Toby Johnson, Yiping Chen, Ling Yang, Canqing Yu, Zheng Bian et al. · 2016 · International Journal of Epidemiology
53. State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease
    Torbjørn Omland, Harvey Douglas White · 2016 · Clinical Chemistry
54. Developing Medicines That Mimic the Natural Successes of the Human Genome
    Sekar Kathiresan · 2015 · Journal of the American College of Cardiology
55. Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
    Alessia d’Aiello, Simone Filomia, Mattia Brecciaroli, Tommaso Sanna, Daniela Pedicino, Giovanna Liuzzo · 2024 · Current Atherosclerosis Reports
56. Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors
    Xinde Chen, Wenwei Xu, Kai Wang, Mingguang Mo, Wei Zhang, Lili Du, Xiaojing Yuan, Yechun Xu, Yiping Wang, Jianhua Shen · 2015 · Journal of Medicinal Chemistry
57. The Role of Colchicine in Acute Coronary Syndromes
    Kaivan Vaidya, Gonzalo Martínez, Sanjay Patel · 2018 · Clinical Therapeutics
58. Reversal of coronary atherosclerosis: Role of life style and medical management
    Christine E Parsons, Pradyumna Agasthi, Farouk Mookadam, Reza Arsanjani · 2018 · Trends in Cardiovascular Medicine
59. The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases
    Charikleia S. Batsika, Anna‐Dimitra D. Gerogiannopoulou, Christiana Mantzourani, Sofia Vasilakaki, George Kokotos · 2021 · Expert Opinion on Drug Discovery
60. Human Genomics and Drug Development
    Amand Floriaan Schmidt, Aroon Dinesh Hingorani, Chris Finan · 2021 · Cold Spring Harbor Perspectives in Medicine
61. Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia
    Art Schuermans, Buu Minh Thanh Truong, Maddalena Ardissino, Rohan Bhukar, Eric A. W. Slob, Tetsushi Nakao, Jacqueline S. Dron, Aeron Small, So Mi Jemma Cho, Zhi Yu et al. · 2024 · JAMA Cardiology
62. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia
    Bashir, Bilal, Schofield, Jonathan, Downie, Paul, France, Michael, Ashcroft, Darren M., Wright, Alison K., Romeo, Stefano, Gouni-Berthold, Ioanna, Maan, Akhlaq, Durrington, Paul N. et al. · 2024 · Frontiers in Cardiovascular Medicine
63. Unraveling the PAF-AH/Lp-PLA2 controversy
    Diana M. Stafforini, Guy A. Zimmerman · 2014 · Journal of Lipid Research
64. Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
    Dimitrios Patoulias, Konstantinos Stavropoulos, Konstantinos P. Imprialos, Vasilios Gabriel Athyros, Haris Grassos, Michael N. Doumas, Charles J. Faselis · 2020 · Current Vascular Pharmacology
65. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2
    Qiufeng Liu, Fubao Huang, Xiaojing Yuan, Kai Wang, Yi Zou, Jianhua Shen, Yechun Xu · 2017 · Journal of Medicinal Chemistry
66. Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source
    Joseph Kamtchum Tatuene, Ali Zohair Nomani, Sarina R. Falcione, Danielle Munsterman, Gina P. Sykes, Twinkle Joy, Elena Spronk, María Isabel Vargas, Glen C. Jickling · 2021 · Frontiers in Neurology
67. The Role of Statins in the Setting of HIV Infection
    Allison Ross Eckard, Grace A. McComsey · 2015 · Current HIV/AIDS Reports
68. The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
    Megan Yu, Sheng‐Feng Tsai, Yu‐Min Kuo · 2017 · International Journal of Molecular Sciences
69. Identification and treatment of the vulnerable coronary plaque
    Anna van Veelen, Niels M R van der Sangen, Josè P.S. Henriques, Bimmer E.P.M. Claessen · 2022 · Reviews in Cardiovascular Medicine
70. The Role of C-reactive Protein in Patient Risk Stratification and Treatment
    Ramón Arroyo‐Espliguero, María Carmen Viana-Llamas, José Alberto Silva, Pablo Avanzas y · 2021 · European Cardiology Review
71. Personalized Cardiovascular Medicine Today
    Alison Blaus, Rajanikanth Madabushi, Michael A. Pacanowski, Martin Rose, Robert N. Schuck, Norman Stockbridge, Robert Temple, Ellis F. Unger · 2015 · Circulation
72. Mechanistic Insights to Target Atherosclerosis Residual Risk
    Mohammad Alkhalil · 2019 · Current Problems in Cardiology
73. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis
    Parveen K. Garg, Robyn L. McClelland, Nancy S. Jenny, Michael H. Criqui, Philip Greenland, Robert S. Rosenson, David S. Siscovick, Neal W. Jorgensen, Mary Cushman · 2015 · Atherosclerosis
74. Inflammatory therapeutic targets in coronary atherosclerosis—from molecular biology to clinical application
    Fabian Linden, Gabriele Domschke, Christian Erbel, Mohammadreza Akhavanpoor, Hugo Albert Katus, Christian Albert Gleissner · 2014 · Frontiers in Physiology
75. Coronary Heart Disease and Genetic Variants with Low Phospholipase A2 Activity
    Linda M. Polfus, Richard A. Gibbs, Eric Boerwinkle · 2015 · New England Journal of Medicine
76. Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF
    Vyala Hanumanthareddy Chaithra, Shancy Petsel Jacob, Chikkamenahalli Lakshminarayana Lakshmikanth, Mosale Seetharam Sumanth, Kandahalli Venkataranganayaka Abhilasha, Chu‐Huang Chen, Anita Thyagarajan‐Sahu, Ravi P. Sahu, Jeffrey Bryant Travers, Thomas M. McIntyre et al. · 2018 · Journal of Lipid Research
77. Alternative strategies in cardiac preclinical research and new clinical trial formats
    Kreutzer, Fabian Philipp, Meinecke, Anna, Schmidt, Kevin, Fiedler, Jan, Thum, Thomas · 2022 · Cardiovascular Research
78. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies
    Maxine Sun, Marie‐Pierre Dubé, Thomas Hennessy, Carl Johann Schultz, Amina Barhdadi, David Rhainds, Graham S. Hillis, Jean‐Claude Tardif · 2022 · International Journal of Cardiology
79. Eosinopenia as an Adverse Marker of Clinical Outcomes in Patients Presenting with Acute Myocardial Infarction
    Mohammad Alkhalil, Aileen Kearney, Mairead Hegarty, Catherine Stewart, Peadar Devlin, Colum G. Owens, Mark S. Spence · 2019 · The American Journal of Medicine
80. Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy
    Pauline Morigny, Doris Kaltenecker, Julia Zuber, Juliano Machado, Lisa Mehr, Foivos‐Filippos Tsokanos, Hanna Kuzi, Chris D. Hermann, Michael Völkl, German Monogarov et al. · 2021 · Journal of Cachexia Sarcopenia and Muscle
81. Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease
    Ola Vedin, Emil Hagström, Ollie Östlund, Álvaro Avezum, Andrzej Budaj, Marcus D Flather, Robert A. Harrington, Wolfgang Köenig, Joseph Soffer, Agneta G Siegbahn et al. · 2017 · International Journal of Cardiology
82. Atherosclerosis: Recent trials, new targets and future directions
    Ricardo Ladeiras‐Lopes, Stefan Agewall, Ahmed A Tawakol, Bart Staels, Evan A. Stein, Robert John Mentz, Adelino Ferreira Leite-Moreira, Faiez M. Zannad, Wolfgang Köenig · 2015 · International Journal of Cardiology
83. Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles
    John Gregson, Daniel F. Freitag, Praveen Surendran, Nathan O. Stitziel, Rajiv Chowdhury, Stephen Burgess, Stephen K. Kaptoge, Pei Gao, James R Staley, Peter Willeit et al. · 2016 · European Journal of Preventive Cardiology
84. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
    Patrícia O. Guimarães, Christopher Bull Granger, Amanda Stebbins, Karen Chiswell, Claes Held, Judith S. Hochman, Susan Krug‐Gourley, Eva Lonn, Renato D. Lópes, Ralph Stewart et al. · 2017 · Journal of the American Heart Association
85. From lipid locus to drug target through human genomics
    Sander W. van der Laan, Eric L. Harshfield, Daiane Hemerich, David Stacey, Angela Wood, Folkert Wouter Asselbergs · 2018 · Cardiovascular Research
86. Colchicine: an affordable anti-inflammatory agent for atherosclerosis
    Peter L. Thompson, Stefan Mark Nidorf · 2018 · Current Opinion in Lipidology
87. Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
    Robert Roberts · 2018 · JACC Basic to Translational Science
88. Group IIA Secretory Phospholipase A 2 , Vascular Inflammation, and Incident Cardiovascular Disease
    Akintunde O. Akinkuolie, Patrick R. Lawler, Audrey Y. Chu, Michael P. Caulfield, Jianying Mu, Bo Ding, Fredrik Nyberg, Robert J. Glynn, Paul M. Ridker, Eva Hurt‐Camejo et al. · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
89. Macrophage: A Key Therapeutic Target in Atherosclerosis?
    Eskandar Taghizadeh, Forough Taheri, Pedram G. Renani, Željko Reiner, Jamshid Gholizadeh Navashenaq, Amirhossein Sahebkar · 2019 · Current Pharmaceutical Design
90. Macrophages
    Ziad Mallat · 2014 · Arteriosclerosis Thrombosis and Vascular Biology
91. In Search of the Vulnerable Plaque
    Sanjay Kaul, Jagat Narula · 2014 · Journal of the American College of Cardiology
92. Untargeted metabolomics predicts the functional outcome of ischemic stroke
    Nai‐Fang Chi, Tzu‐Hao Chang, Chen-Yang Lee, Yu‐Wei Wu, Ting-An Shen, Lung Chan, Yih-Ru Chen, Hung‐Yi Chiou, Chung Y. Hsu, Chaur‐Jong Hu · 2020 · Journal of the Formosan Medical Association
93. Impact of Kidney Function on the Blood Proteome and on Protein Cardiovascular Risk Biomarkers in Patients With Stable Coronary Heart Disease
    Joseph Yuan‐Mou Yang, Edward N. Brody, Ashwin C. Murthy, Robert E. Mehler, Sophie J. Weiss, Robert Kirk DeLisle, Rachel M. Ostroff, Stephen A. Williams, Peter Ganz · 2020 · Journal of the American Heart Association
94. Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque
    Michał Kowara, Agnieszka Cudnoch‐Jędrzejewska · 2021 · International Journal of Molecular Sciences
95. Bacterial exploitation of phosphorylcholine mimicry suppresses inflammation to promote airway infection
    Christopher A. Hergott, Aoife M. Roche, Nikhil A. Naidu, Clementina Mesaros, Ian A. Blair, Jeffrey N. Weiser · 2015 · Journal of Clinical Investigation
96. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial
    Claudia Pedroza, Jon E. Tyson, Abhik Das, Abbot R. Laptook, Edward F. Bell, Seetha Shankaran · 2016 · Trials
97. Mechanisms Underlying Vascular Inflammaging: Current Insights and Potential Treatment Approaches
    Ying Zeng, Francesco Buonfiglio, Jingyan Li, Norbert Pfeiffer, Adrian Gericke · 2025 · Aging and Disease
98. Emerging Risk Factors for Stroke
    Jemma C. Hopewell, Robert Clarke · 2016 · Stroke
99. Statins to improve cardiovascular outcomes in treated HIV infection
    Chris Todd Longenecker, Allison Ross Eckard, Grace A. McComsey · 2015 · Current Opinion in Infectious Diseases
100. Leveraging human genetics to guide drug target discovery
     Nathan O. Stitziel, Sekar Kathiresan · 2016 · Trends in Cardiovascular Medicine